Canadian Public Reimbursement Timelines
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
One of Innovative Medicines Canada’s guiding principles is to offer solutions that address challenges in the Canadian health system; access to new medicines is one such challenge.
We believe that information-sharing is essential to collaboratively finding solutions and ensuring the sustainability of Canadian health systems.
Toward this effort, Innovative Medicines Canada (IMC) has put together a pCPA Trends Update page to provide drug reimbursement updates and trends in Canada and OECD countries.
These resources are prepared and updated by IMC using aggregated and independently collected data. Sources include data from IQVIA International Reimbursement Comparison, Health Canada, Canadian Agency for Drugs and Technologies in Health (CADTH), Institut national d’excellence en santé et services sociaux (INESSS), pan-Canadian Pharmaceutical Alliance (pCPA), and various Canadian provincial formularies.
Trends related to time to access, volume of negations, and pCPA performance metrics are identified.
CANADIAN PUBLIC REIMBURSEMENT TIMELINES RESOURCES
Drug Reimbursement Timeline by Stages 2019-2020
Source: IMC analysis of IQVIA International Reimbursement Comparison data and IQVIA Public Reimbursement data. CADTH and provincial listing timelines are for drugs with a pCPA LOI in the respective year. Provincial Listing is the average time from pCPA completed negotiation to provincial listing dates for drugs with a pCPA LOI. CADTH, pCPA, and provincial listing timelines are arithmetic averages.
Days from Authorization to Reimbursement 2012-2018
Source: IMC analysis of IQVIA International Reimbursement Comparison data. Arithmetic average of days from market authorization in each country to reimbursement in the same country. 632 days for Canada represents the best-case scenario (i.e. time from Health Canada approval to first provincial listing date).
pCPA timeline data
Source: IMC analysis of pCPA data collected from pCPA Canada and CADTH data collected from CADTH Reimbursement Review Reports.
Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations and CADTH data collected from CADTH Reimbursement Review Reports.
Source: IMC analysis of pCPA data collected from pCPA Canada.
pCPA resources
Innovative Agreements Framework
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
Search for Specific Brand Name Drug Negotiations Status with the pCPA
Use this tool to search for brand name drugs to view their current negotiation status.
pCPA overview of the Negotiation Process
Learn more about the negotiation process from the pCPA.
Additional analysis of Canadian reimbursement
- MORSE Consulting’s review of the latest trends and insights
- MORSE Consulting’s 4th Annual pCPA Year in Review Infographic (2020 Edition)
- MORSE Consulting pCPA February 2021 Trends and Insights
